V. Vanquickelberghe

发表

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

P. Sonneveld, M. Mohty, M. Béné, 2021, The Lancet. Oncology.

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

H. Goldschmidt, P. Sonneveld, P. Moreau, 2020, Immunotherapy.

Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

P. Sonneveld, M. Béné, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Spatial distribution and biodiversity patterns of the hyperbenthos along NE Atlantic continental margins

V. Vanquickelberghe, 2005 .

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

P. Sonneveld, V. V. D. van der Velden, M. Mohty, 2021, Blood.

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

P. Sonneveld, P. Moreau, C. D. de Boer, 2020, EJHaem.

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

P. Sonneveld, P. Moreau, T. Facon, 2021, Haematologica.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.

P. Sonneveld, P. Moreau, L. Frenzel, 2020, The Lancet. Haematology.

Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

P. Sonneveld, P. Moreau, T. Facon, 2019, Clinical Lymphoma Myeloma and Leukemia.

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

M. Boccadoro, R. Mina, E. Katodritou, 2023, The New England journal of medicine.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

M. Vekemans, M. Macro, C. Touzeau, 2024, The Lancet Oncology.